Canada Pension Plan Investment Board Takes $609,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Canada Pension Plan Investment Board bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,300 shares of the medical research company's stock, valued at approximately $609,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Charles River Laboratories International in the third quarter valued at $601,000. JPMorgan Chase & Co. grew its position in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after buying an additional 85,759 shares during the last quarter. Veracity Capital LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $589,000. Lord Abbett & CO. LLC boosted its holdings in shares of Charles River Laboratories International by 5.8% in the third quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock worth $21,413,000 after buying an additional 5,959 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $1.19 during midday trading on Wednesday, reaching $118.48. 1,499,116 shares of the company's stock were exchanged, compared to its average volume of 931,942. The firm has a market capitalization of $5.82 billion, a PE ratio of 789.87, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company's 50 day simple moving average is $143.94 and its two-hundred day simple moving average is $169.71. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.46 earnings per share. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

CRL has been the subject of several research reports. Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. UBS Group reaffirmed a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $182.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).